Novavax Inc vs Tilray Brands Inc — how do they compare? Novavax Inc trades at $8.06 (market cap $1.30B), while Tilray Brands Inc trades at $4.24 (market cap $524.07M). The key difference: Novavax Inc is far larger — about 2.5× Tilray Brands Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | TLRY | |
|---|---|---|
Market Cap | $1.30B | $524.07M |
Sector | Health | Health |
52-Week High | $11.19 | $21.00 |
52-Week Low | $6.22 | $4.23 |
Enterprise Value | $800.50M | $621.22M |
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →